questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Antienzymes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Inhibiteurs enzymatiques
Tests de laboratoire
Symptômes
Troubles digestifs
Tests diagnostiques
Anticorps
Imagerie médicale
Évaluation des organes
Marqueurs biochimiques
Enzymes
Symptômes
5
Symptômes
Troubles métaboliques
Douleur
Troubles digestifs
Enzymes
Symptômes spécifiques
Asymptomatique
Inhibition enzymatique
Évolution des symptômes
Traitement
Prévention
5
Prévention
Alimentation équilibrée
Contrôles médicaux
Détection précoce
Éducation médicale
Médicaments
Traitements
5
Chimiothérapie
Anticancéreux
Administration de médicaments
Voies d'administration
Effets secondaires
Nausées
Médecine personnalisée
Inhibition enzymatique
Complications
5
Complications
Troubles métaboliques
Maladies chroniques
Diabète
Surdosage
Effets indésirables
Gestion des complications
Suivi médical
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Âge
Dégradation enzymatique
Maladies auto-immunes
Inhibition enzymatique
Médicaments
Interférence enzymatique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antienzymes : Questions médicales les plus fréquentes",
"headline": "Antienzymes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antienzymes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-26",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antienzymes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"url": "https://questionsmedicales.fr/mesh/D045504",
"about": {
"@type": "MedicalCondition",
"name": "Mécanismes moléculaires de l'action pharmacologique",
"code": {
"@type": "MedicalCode",
"code": "D045504",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"alternateName": "5-Lipoxygenase-Activating Protein Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058946",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des protéines activatrices de la 5-lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D058946",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.086"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"alternateName": "Acetaldehyde Dehydrogenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065086",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'acétaldéhyde déshydrogénase",
"code": {
"@type": "MedicalCode",
"code": "D065086",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.089"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'adénosine désaminase",
"alternateName": "Adenosine Deaminase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058892",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'adénosine désaminase",
"code": {
"@type": "MedicalCode",
"code": "D058892",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.092"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des adénylate cyclases",
"alternateName": "Adenylyl Cyclase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000067956",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des adénylate cyclases",
"code": {
"@type": "MedicalCode",
"code": "D000067956",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.108"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la calcineurine",
"alternateName": "Calcineurin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065095",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la calcineurine",
"code": {
"@type": "MedicalCode",
"code": "D065095",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.174"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'anhydrase carbonique",
"alternateName": "Carbonic Anhydrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D002257",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'anhydrase carbonique",
"code": {
"@type": "MedicalCode",
"code": "D002257",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"alternateName": "Gamma Secretase Inhibitors and Modulators",
"url": "https://questionsmedicales.fr/mesh/D000091062",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs et modulateurs de la gamma-secrétase",
"code": {
"@type": "MedicalCode",
"code": "D000091062",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.315"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"alternateName": "Cytochrome P-450 Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065607",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des enzymes du cytochrome P-450",
"code": {
"@type": "MedicalCode",
"code": "D065607",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"alternateName": "Cytochrome P-450 CYP1A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065609",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP1A2",
"code": {
"@type": "MedicalCode",
"code": "D065609",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.120"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"alternateName": "Cytochrome P-450 CYP2B6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065686",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2B6",
"code": {
"@type": "MedicalCode",
"code": "D065686",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.260"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"alternateName": "Cytochrome P-450 CYP2C8 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065687",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C8",
"code": {
"@type": "MedicalCode",
"code": "D065687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.308"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065689",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065689",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.319"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065688",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.329"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"alternateName": "Cytochrome P-450 CYP2D6 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065690",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2D6",
"code": {
"@type": "MedicalCode",
"code": "D065690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.368"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"alternateName": "Cytochrome P-450 CYP2E1 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065691",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP2E1",
"code": {
"@type": "MedicalCode",
"code": "D065691",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.421"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"alternateName": "Cytochrome P-450 CYP3A Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065692",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du cytochrome P-450 CYP3A",
"code": {
"@type": "MedicalCode",
"code": "D065692",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.335.503"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Antifoliques",
"alternateName": "Folic Acid Antagonists",
"url": "https://questionsmedicales.fr/mesh/D005493",
"about": {
"@type": "MedicalCondition",
"name": "Antifoliques",
"code": {
"@type": "MedicalCode",
"code": "D005493",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de désacétylase d'histone",
"alternateName": "Histone Deacetylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D056572",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de désacétylase d'histone",
"code": {
"@type": "MedicalCode",
"code": "D056572",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.360"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'intégrase",
"alternateName": "Integrase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019429",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'intégrase",
"code": {
"@type": "MedicalCode",
"code": "D019429",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la lipoxygénase",
"alternateName": "Lipoxygenase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D016859",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la lipoxygénase",
"code": {
"@type": "MedicalCode",
"code": "D016859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.480"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la monoamine oxydase",
"alternateName": "Monoamine Oxidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D008996",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la monoamine oxydase",
"code": {
"@type": "MedicalCode",
"code": "D008996",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.616"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"alternateName": "Nucleic Acid Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D019384",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse d'acide nucléique",
"code": {
"@type": "MedicalCode",
"code": "D019384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"alternateName": "Ornithine Decarboxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D065108",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'ornithine décarboxylase",
"code": {
"@type": "MedicalCode",
"code": "D065108",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase",
"alternateName": "Phosphodiesterase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D010726",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase",
"code": {
"@type": "MedicalCode",
"code": "D010726",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-3",
"alternateName": "Phosphodiesterase 3 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058987",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-3",
"code": {
"@type": "MedicalCode",
"code": "D058987",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-4",
"alternateName": "Phosphodiesterase 4 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-4",
"code": {
"@type": "MedicalCode",
"code": "D058988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phosphodiestérase-5",
"alternateName": "Phosphodiesterase 5 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D058986",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phosphodiestérase-5",
"code": {
"@type": "MedicalCode",
"code": "D058986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.735.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"alternateName": "Phosphoinositide-3 Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000081082",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des phosphoinositide-3 kinases",
"code": {
"@type": "MedicalCode",
"code": "D000081082",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.736"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la phospholipase A2",
"alternateName": "Phospholipase A2 Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064801",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la phospholipase A2",
"code": {
"@type": "MedicalCode",
"code": "D064801",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.737"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D064800",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.740"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéases",
"alternateName": "Protease Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011480",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéases",
"code": {
"@type": "MedicalCode",
"code": "D011480",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"alternateName": "Angiotensin-Converting Enzyme Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000806",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de l'enzyme de conversion de l'angiotensine",
"code": {
"@type": "MedicalCode",
"code": "D000806",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des vasopeptidases",
"alternateName": "Vasopeptidase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075563",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des vasopeptidases",
"code": {
"@type": "MedicalCode",
"code": "D000075563",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.085.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cystéine protéinase",
"alternateName": "Cysteine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015853",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cystéine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015853",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des caspases",
"alternateName": "Caspase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061945",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des caspases",
"code": {
"@type": "MedicalCode",
"code": "D061945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.325.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"alternateName": "Matrix Metalloproteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061965",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de métalloprotéinases matricielles",
"code": {
"@type": "MedicalCode",
"code": "D061965",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.610"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs du protéasome",
"alternateName": "Proteasome Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D061988",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs du protéasome",
"code": {
"@type": "MedicalCode",
"code": "D061988",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.705"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la rénine",
"alternateName": "Renin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092502",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la rénine",
"code": {
"@type": "MedicalCode",
"code": "D000092502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.753"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la sérine protéinase",
"alternateName": "Serine Proteinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D015842",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la sérine protéinase",
"code": {
"@type": "MedicalCode",
"code": "D015842",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"alternateName": "Serine Peptidase Inhibitors, Kazal Type",
"url": "https://questionsmedicales.fr/mesh/D000074162",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de serine peptidase de type Kazal",
"code": {
"@type": "MedicalCode",
"code": "D000074162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.562"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Serpines",
"alternateName": "Serpins",
"url": "https://questionsmedicales.fr/mesh/D015843",
"about": {
"@type": "MedicalCondition",
"name": "Serpines",
"code": {
"@type": "MedicalCode",
"code": "D015843",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.675"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs trypsiques",
"alternateName": "Trypsin Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D014361",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs trypsiques",
"code": {
"@type": "MedicalCode",
"code": "D014361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.745.800.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéines kinases",
"alternateName": "Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D047428",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéines kinases",
"code": {
"@type": "MedicalCode",
"code": "D047428",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs des Janus kinases",
"alternateName": "Janus Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000075242",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D000075242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"alternateName": "Tyrosine Protein Kinase Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D000092004",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de protéine-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000092004",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.755.875"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la synthèse protéique",
"alternateName": "Protein Synthesis Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D011500",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la synthèse protéique",
"code": {
"@type": "MedicalCode",
"code": "D011500",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.760"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la pompe à protons",
"alternateName": "Proton Pump Inhibitors",
"url": "https://questionsmedicales.fr/mesh/D054328",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la pompe à protons",
"code": {
"@type": "MedicalCode",
"code": "D054328",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.848"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Agents découplants",
"alternateName": "Uncoupling Agents",
"url": "https://questionsmedicales.fr/mesh/D014475",
"about": {
"@type": "MedicalCondition",
"name": "Agents découplants",
"code": {
"@type": "MedicalCode",
"code": "D014475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389.936"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"alternateName": "Enzyme Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xiaoxi Liu",
"url": "https://questionsmedicales.fr/author/Xiaoxi%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Robert S Magin",
"url": "https://questionsmedicales.fr/author/Robert%20S%20Magin",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Nathan J Schauer",
"url": "https://questionsmedicales.fr/author/Nathan%20J%20Schauer",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Sara J Buhrlage",
"url": "https://questionsmedicales.fr/author/Sara%20J%20Buhrlage",
"affiliation": {
"@type": "Organization",
"name": "Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu."
}
},
{
"@type": "Person",
"name": "R Gentry Wilkerson",
"url": "https://questionsmedicales.fr/author/R%20Gentry%20Wilkerson",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Effect of Subjective Exercise Experience on Exercise Behavior and Amount of Exercise in Children and Adolescents: The Mediating Effect of Exercise Commitment.",
"datePublished": "2022-08-30",
"url": "https://questionsmedicales.fr/article/36078545",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph191710829"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exercise and Exercise Mimetics for the Treatment of Musculoskeletal Disorders.",
"datePublished": "2022-07-26",
"url": "https://questionsmedicales.fr/article/35881303",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11914-022-00739-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exercising is good for the brain but exercising outside is potentially better.",
"datePublished": "2023-01-20",
"url": "https://questionsmedicales.fr/article/36670116",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-26093-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of acute exercise on memory: Considerations of exercise intensity, post-exercise recovery period and aerobic endurance.",
"datePublished": "2022-11-18",
"url": "https://questionsmedicales.fr/article/36401115",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3758/s13421-022-01373-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "A microbiome exercise.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37410844",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/science.adi6329"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antienzymes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antienzymes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antienzymes",
"description": "Comment diagnostiquer une inhibition enzymatique ?\nQuels symptômes indiquent une inhibition enzymatique ?\nQuels tests sont utilisés pour détecter les antienzymes ?\nPeut-on utiliser l'imagerie pour diagnostiquer ?\nQuels marqueurs biochimiques sont associés aux antienzymes ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Exercise#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antienzymes",
"description": "Quels sont les symptômes d'une inhibition enzymatique ?\nL'inhibition enzymatique peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques selon l'enzyme inhibée ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Exercise#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antienzymes",
"description": "Comment prévenir l'inhibition enzymatique ?\nLes vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?\nY a-t-il des habitudes de vie à adopter ?\nLes contrôles médicaux réguliers sont-ils importants ?\nL'éducation sur les médicaments est-elle nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Exercise#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antienzymes",
"description": "Quels traitements existent pour l'inhibition enzymatique ?\nLes antienzymes sont-ils utilisés en chimiothérapie ?\nComment les inhibiteurs enzymatiques sont-ils administrés ?\nY a-t-il des effets secondaires aux antienzymes ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Exercise#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antienzymes",
"description": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?\nL'inhibition enzymatique peut-elle entraîner des maladies chroniques ?\nY a-t-il des risques de surdosage avec les antienzymes ?\nComment gérer les complications liées aux antienzymes ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Exercise#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antienzymes",
"description": "Quels sont les facteurs de risque d'inhibition enzymatique ?\nL'âge influence-t-il le risque d'inhibition enzymatique ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie affecte-t-il le risque ?\nLes médicaments peuvent-ils être des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D004791?mesh_terms=Exercise#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition enzymatique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses biochimiques évaluent l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une inhibition enzymatique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, la douleur abdominale ou des troubles digestifs peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les antienzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique et les dosages spécifiques d'anticorps sont courants."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique aux antienzymes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés aux antienzymes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'enzymes spécifiques dans le sang peuvent indiquer une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une inhibition enzymatique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs abdominales, nausées, et troubles métaboliques."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle causer des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des douleurs dues à des troubles digestifs ou métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques selon l'enzyme inhibée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes varient selon l'enzyme affectée, comme la lactase ou la lipase."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré une inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver si l'inhibition persiste sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inhibition enzymatique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'évitement de substances toxiques peuvent aider."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des inhibitions enzymatiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui causent des inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter l'alcool et le tabac peut réduire le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes enzymatiques."
}
},
{
"@type": "Question",
"name": "L'éducation sur les médicaments est-elle nécessaire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les effets des médicaments aide à prévenir les inhibitions enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'inhibition enzymatique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments spécifiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "Les antienzymes sont-ils utilisés en chimiothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains antienzymes sont utilisés pour cibler des enzymes dans les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Comment les inhibiteurs enzymatiques sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie orale, intraveineuse ou topique selon le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux antienzymes ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées, des éruptions cutanées ou des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement est souvent adapté en fonction de la cause et de la gravité de l'inhibition."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'inhibition enzymatique ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles métaboliques ou des maladies organiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'inhibition enzymatique peut-elle entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inhibition prolongée peut contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de surdosage avec les antienzymes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un surdosage peut entraîner des effets indésirables graves et des complications."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux antienzymes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition enzymatique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies héréditaires et des habitudes alimentaires."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'inhibition enzymatique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente souvent avec l'âge en raison de la dégradation enzymatique naturelle."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque d'inhibition enzymatique."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils être des facteurs de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec l'activité enzymatique et augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Biology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. saraj_buhrlage@dfci.harvard.edu.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: gwilkerson@som.umaryland.edu.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Emergency Medicine, University of Maryland School of Medicine, 110 South Paca Street, 6th Floor, Suite 200, Baltimore, MD 21201, USA. Electronic address: https://twitter.com/critcareguys.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR5068, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Publications dans "Antienzymes" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR5068, CNRS, Université Paul Sabatier Toulouse III, 31062 Toulouse, France.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, United States. Electronic address: kychoi@utmb.edu.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Institute of Translational Medicine, Department of Pharmacology, School of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China.
Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou, Jiangsu, 225001, People's Republic of China.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Publications dans "Antienzymes" :
1 publication dans cette catégorie
Affiliations :
Clinical Chemistry-Biochemistry, International Hellenic University, 57400 Thessalonik, Greece.
Publications dans "Antienzymes" :
To explore the influencing factors that restrict the exercise behavior of children and adolescents, investigate the effect of subjective exercise experience on exercise behavior, and reveal the mediat...
The Subjective Exercise Experience Scale (SEES), Exercise Commitment Scale (ECC), and Physical Exercise Rating Scale (PARS-3) were used to conduct a questionnaire survey on 600 children and adolescent...
(1) Among children and adolescents, boys' exercise commitment and exercise behavior were significantly higher than girls', and there was no significant gender difference in subjective exercise experie...
The exercise behavior of children and adolescents was not only directly affected by subjective exercise experience, but also affected by the mediating effect of exercise commitment, and maintaining a ...
The incidence of musculoskeletal disorders affecting bones, joints, and muscles is dramatically increasing in parallel with the increased longevity of the worldwide population, severely impacting on t...
Both the skeletal muscle and the bone are involved in a complex crosstalk determining, in part through tissue-specific and inflammatory/immune released factors, the occurrence of musculoskeletal disor...
It is well known that exercise increases cognitive function. However, the environment in which the exercise is performed may be just as important as the exercise itself. Time spent in natural outdoor ...
Accumulating research demonstrates that acute exercise can enhance long-term episodic memory. However, it is unclear if there is an intensity-specific effect of acute exercise on long-term episodic me...
Gut-brain connections drive the motivation to work out....
Physical activity had been reported among doctors-in-training, with very few focusing on attending doctors. This study aimed to evaluate the physical activity, particularly exercise, of Thai doctors a...
Thai doctors who participated in the hospital's CSR service, which was conducted between Feb 14, 2022, to Oct 31, 2022, were verbally informed along with an information sheet about this parallel study...
The median age of 1187 doctors was 45.0 years. Slightly over half were female (55.4%) or worked ≤ 40 hours/week (55.3%). The presence of illnesses was found in 55.9%, irregular health surveillance in ...
Only 30% of Thai doctors had a high level of exercise. The significant independent factors for low-level exercise were younger age, female, working load, irregular health surveillance, and no/ low fib...
Long-term exercise intolerance and functional limitations are common after an episode of acute pulmonary embolism (PE), despite 3 to 6 months of anticoagulation. These persistent symptoms are reported...
Recent studies indicate that acute exercise, whether aerobic exercise (AE) or resistance exercise (RE), improves cognitive function. However, the effects on cognitive function of combined exercise (CE...
Within-subject design with counterbalancing....
Fifteen healthy men with a sedentary lifestyle in the previous three months were recruited. The participants were assessed for muscular fitness after performing four upper body exercises for a 10-repe...
Acute CE led to a significantly shorter response time compared to SC (...
A single session of moderate-intensity CE improved response time in the SCWT, comparable to RE. CE shows promise for enhancing cognitive function, warranting further research on its benefits and other...
Maladaptive exercise (i.e., driven and/or compensatory exercise) is common in binge-spectrum eating disorders (EDs; e.g., bulimia nervosa, binge ED) and associated with adverse treatment outcomes. Alt...
We used latent profile analysis (LPA) to identify pre-exercise affective profiles of 661 exercise episodes among 84 individuals with binge-spectrum EDs and examined associations between LPA-identified...
A two-profile solution best fit our data: Profile 1 (n = 174), 'positive affectivity,' and Profile 2 (n = 487), 'negative affectivity.' Episodes in the 'negative affectivity' profile were more likely ...
Results support two phenotypes of exercise episodes, and differential associations of these phenotypes with adaptive and maladaptive motivations for exercise....
Pulmonary hypertension (PH) is a frequent complication in COPD and it is associated with decreased exercise capacity and poor prognosis. We hypothesized that even in COPD patients without significant ...
Consecutive COPD patients with clinically indicated right heart catheterization and resting mean pulmonary arterial pressure (mPAP) < 25 mmHg and age- and sex-matched controls with the same limits of ...
We included n = 26 COPD patients (female/male: 16/10, 66 ± 11 yr, FEV...
Even in the absence of significant PH at rest, COPD patients reveal characteristic abnormalities in pulmonary hemodynamics during exercise, which may represent an important exercise-limiting factor....